..., instructions or products referred to in the content or advertisements. Androgens Cytosine arabinoside Myelodysplastic syndromes Hemato-Oncology and Hemato-Immunology. Proc. 2nd Int. Conf.. Catania 1986 Acta hacmat. 78: suppl. 1, pp. 109-115 (1987) © 1987 S. Karger AG, Basel 0001-5792/87/0787-0109 S...

...Roberto Marra; Livio Pagano; Valerio De Stefano; Giuseppe Leone; Bruno Bizzi Fourteen patients with hematologic neoplasia (11 acute myeloid leukemias, 2 non-Hodgkin’s lymphomas and 1 blast crisis of chronic myeloid leukemia) who underwent high-dose cytosine arabinoside (HIDARAC) therapy...

... that busulfan (BU) was more effective against the self-renewal of blast progenitors than against the terminal divisions. As reported previously, cytosine arabinoside (Ara-C) is more effective against self-renewal and adriamycin (ADR) is more effective against terminal divisions. To determine the reason why...

... and cytosine arabinoside (ARA-C) 200 mg/m 2 /day by continuous infusion on days 1-7. Complete remission (CR) was achieved in 10 of 20 (50%) patients (3 refractory and 7 relapsed). Median duration of CR was 5 months (range 2-9). The treatment was associated with minimal extrahematologic toxicity...

...Ali Keskin; Murat Tombuloğlu; Muvaffak A. Atamer; Filiz Büyükkeçeci Thirty adult patients with relapsing or refractory acute leukemia were treated with mitoxantrone 10 mg/m2 daily by 20-min intravenous infusion for 5 days and cytosine arabinoside (Ara-C) 200 mg/m 2 daily by continuous infusion...

...C.K. Arthur; D.D.F. Ma Thirty patients with chronic myeloid leukemia in chronic phase and less than 1 year from diagnosis were treated with a combination of interferon alfa-2a (IFN) 9 million units daily continuously and intermittent low-dose cytosine arabinoside (Ara-C) 20 mg/m 2 daily for 21 days...

...) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy). G-CSF (50 μg/m 2 /day, subcutaneous injection) was administered simultaneously with a continuous intravenous infusion of Ara-C (70...

...Hiroshi Handa; Sachiko Motohashi; Kazuo Isozumi; Satoru Komatsumoto; Masaharu Nara We describe a 69-year-old Japanese male with acute leukemia with a CD7+ and CD56+ immunophenotype presenting with multiple lymphadenopathy. He was treated with idarubicin and cytosine arabinoside. Although...

... of all-trans retinoic acid (ATRA) and cytosine arabinoside (ARA-C), employed alone, in combination or in sequence, on freshly isolated cells from 10 patients with chronic-phase CML. Our cell cultures showed that both ATRA and ARA-C were able to induce apoptosis in CML cells, even if ARA-C resulted more...